Navigation Links
Amgen And Zhejiang Beta Pharma Announce Planned Joint Venture In China
Date:5/9/2013

ience to dramatically improve people's lives. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

About Zhejiang Beta Pharma Co., Ltd.
Zhejiang Beta Pharma is a leading innovative pharmaceutical company in China with fully integrated capabilities that include R&D, GMP manufacture, sales and marketing.  We were founded in 2003 and are headquartered in Hang-Zhou with R&D operations in Beijing.  Over the last 10 years, we have been dedicated to the development of novel therapeutics and launched Icotinib in 2011 for the treatment of NSCLC patients in China.  Going forward, we will continue to focus on pharmaceutical innovation so that we can benefit many more patients.  For more information, visit www.betapharma.com.cn.

About Vectibix
Vectibix is a prescription medicine used for the treatment of metastatic colorectal cancer (mCRC). It is grouped within a class of medications called biologics, which are therapies derived from human cells. Vectibix is approved in more than 40 countries. 

Vectibix is the first fully human anti-epidermal growth factor receptor (EGFR) antibody approved by the U.S. Food and Drug Administration (FDA) for the treatment of metastatic colorectal cancer (mCRC). Vectibix was approved in the U.S. in September 2006 as a single agent for the treatment of metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival with Vectibix.

Retrospective subset analyses of metastatic colorectal cancer trials have not shown a treatment benefit for Vectibix in patients whose tumors had KRAS mutations in codon 12
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  WebMD Health Corp. (NASDAQ: ... health information, today announced an exclusive White ... Action Plan for Combating Antibiotic-Resistant Bacteria . ... urgency and importance of addressing antibiotic-resistant bacteria ... health.    The WebMD interview, available ...
(Date:3/26/2015)... VANCOUVER, British Columbia, March 26, 2015  OncoGenex ... a summary of clinical developments and announced fourth ... Clinical Developments and Anticipated Near-term MilestonesCustirsen ... and Teva agreed to negotiate the termination of ... Negotiations of the final termination agreement are ongoing. ...
(Date:3/26/2015)... 2015  CCS Medical ("CCS"), one of the ... patients with chronic conditions, has named Rodney ... effective March 23.  Mr. Carson joins CCS from ... was President of Operations. Prior ... Vice President of Operations at NationsHealth, (n/k/a Convey ...
Breaking Medicine Technology:Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 2Exclusive: WebMD Interviews President Obama About Plan for Combating Antibiotic Resistance 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 2OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 3OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 4OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 5OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 6OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 7OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Fourth Quarter and Year End 2014 8CCS Medical Team Hires Industry Operator Rodney Carson as CEO 2
... Incorporated (Nasdaq: ARAY ), the premier radiation oncology ... Euan S. Thomson, Ph.D., is scheduled to present at the ... City on Tuesday November 15, 2011 at 10:30 a.m. EST/7:30 ... the Stephens Fall Investment Conference in New York City on ...
... PARSIPPANY, N.J., Nov. 10, 2011 Columbia Laboratories, Inc. ... (NYSE: WPI ), today confirmed that the ... Food and Drug Administration (FDA) is scheduled to review ... for the reduction of risk of preterm birth in ...
Cached Medicine Technology:Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 2Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 3Columbia Laboratories and Watson Pharmaceuticals Confirm FDA Advisory Committee to Review Preterm Birth NDA 4
(Date:3/27/2015)... While deep learning was the topic of many conversations ... the CEO of one start-up spoke passionately about using fast ... beyond the generally-agreed ceiling of 120 years. , Insilico Medicine, ... 12 companies recognized as the hottest GPU-powered startups in the ... Emerging Companies Summit have business models focused on self-driving ...
(Date:3/27/2015)... KING OF PRUSSIA, PA and LONDON, UK (PRWEB) March ... and current President of DrugDev SiteStart Melissa (Liss) Easy ... Under 40. , The 40 Under 40 list ... of age for their professional accomplishments and community involvement. ... and profiled in a special supplement of the Philadelphia ...
(Date:3/27/2015)... The report “CountryFocus: Healthcare, Regulatory and ... information on and analysis of the healthcare, regulatory and ... US in 2013 amounted to 316.1 million, having grown ... from 2008. The country’s increasingly elderly population and corresponding ... to boost the growth of the pharmaceutical market, which ...
(Date:3/27/2015)... SMI (Silicon Microstructures, Inc.), a global MEMS pressure ... MEMS based ultra-miniature pressure sensor designed especially for the ... 220um x 75um provides ample space for 1-French catheter ... industry leading in vivo drift performance of 2 ... pressure range from 0 to 1,100 mmHg absolute. ...
(Date:3/27/2015)... Bellevue, WA (PRWEB) March 27, 2015 ... it can be hard to know where to begin. ... an experienced Seattle trucking accident attorney, offers accident victims ... financial, and legal assistance to ensure their personal injury ... eBook begins by describing the first actions that should ...
Breaking Medicine News(10 mins):Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3Health News:DrugDev Founder Melissa Easy is 2015 Philadelphia Business Journal 40 Under 40 Honoree 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 2Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 3Health News:US Pharmaceutical Market worth $548.4 billion by 2020 Says a New Report Available at RnRMarketResearch.com 4Health News:SMI Launches Catheter Mountable Pressure Sensor 2Health News:Dax Jones Updated eBook on Trucking Accidents Offers Helpful Information to Crash Victims 2
... , KENILWORTH, N.J., Aug. 11 ... an agreement with Orchid Chemicals & Pharmaceuticals Ltd. and Orgenus ... formulations of CLARINEX(R) (desloratadine). , , ... filed and consolidated since 2006 in the U.S. District Court ...
... , Survey seeks feedback from public to help ... CHICAGO, Aug. 11 Participate in the American Dental Association (ADA) ... and become eligible to win a $150 Amazon.com gift certificate and, at the ... ADA.org provides news and information on hundreds of dental topics, ranging from ...
... , MOUNTAIN VIEW, Calif., Aug. 11 VIVUS, ... and commercialization of novel therapeutic products, today reported its financial results for the ... Second Quarter Results , , Net loss ... as compared to net income of $3.6 million, or $0.06 per share, for ...
... , , VERNON HILLS, ... provider of vascular access management services, today announced the launch ... integrated network for physicians to act as one to deliver ... new program has the potential to ultimately save money for ...
... , , SAN BERNARDINO, Calif., Aug. 11 ... food junkies, the all new comic book superhero, Super Nutricia, created by Inland ... children. This is the first ever female superhero from IEHP,s squad of masked ... (Photo: http://www.newscom.com/cgi-bin/prnh/2 0 090811/DC6 0 ...
... newborns experiencing a fatal lack of oxygen, study finds , ... there,s been a nearly 40 percent drop in the risk ... infants in Scotland, new research has found. , The major ... of deaths caused by a lack of oxygen for the ...
Cached Medicine News:Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 2Health News:Schering-Plough Announces Resolution of Litigations on U.S. Marketing of Generic Forms of Solid Oral Dosage Forms of CLARINEX(R) 3Health News:American Dental Association Web Survey Offers Chance at $150 Gift Certificate 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 2Health News:VIVUS Reports Second Quarter 2009 Financial Results 3Health News:VIVUS Reports Second Quarter 2009 Financial Results 4Health News:VIVUS Reports Second Quarter 2009 Financial Results 5Health News:VIVUS Reports Second Quarter 2009 Financial Results 6Health News:VIVUS Reports Second Quarter 2009 Financial Results 7Health News:Lifeline Vascular Access Launches New Platform for Physicians to Share Best Practices and Improve Vascular Access Care 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 2Health News:Introducing All-New IEHP Superhero to Battle Childhood Obesity 3Health News:Delivery-Related Infant Deaths Decline in Scotland 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: